Twitter Thread by CNN Philippines

CNN Philippines
@cnnphilippines

THREAD: Senator Ping Lacson delivers a privilege speech on the government's vaccination plan | LIVE https://t.co/R4i9422ym2

Tweets by our digital producer @daninakpil




Lacson on Sinovac vaccine: Our officials were both tongue-tied and stuttering. I could not understand why we are being kept in the dark with the price negotiations with Sinovac while our neighboring countries cannot be more transparent about it

Lacson says countries like Thailand and Indonesia have been transparent with their vaccine procurement of Sinovac

Thailand has procured the Sinovac vaccine for ■683. 30 and ■240, respectively.

Lacson: Will somebody explain the ■1,814.75 per dose price of Sinovac vaccine?



Lacson: It appears that our initial lock in agreement will not be covered by the ludicrous 300% markdown

Lacson says he is not accusing anyone of corruption: It defies logic to suspect an attempt to overprice the vaccine.

Lacson: When there's an attempt at overpricing, isn't it logical to think na may kikita ng limpak limpak?

Lacson: Our vaccine program officials brought more confusion and bewilderment in their rush to procure Sinovac


Lacson notes that Sinovac still has no FDA approval and has no clinical phase three trial results for EUA

RELATED: Pfizer is the first developer to be granted emergency use authorization (EUA) in the Philippines, while Sinovac, AstraZeneca, and Gamaleya have submitted their EUA applications https://t.co/PjMth4zeRT

> The Philippine government is in talks with developers to secure millions of COVID-19 vaccine doses, enough to inoculate up to 70 million people https://t.co/jj8T02XpvP pic.twitter.com/ymJnLj9MNm
>
> — CNN Philippines (@cnnphilippines) January 18, 2021

Lacson presents a study of the efficacy rate of the Sinovac vaccine.

Lacson says Sinovac is one of the most expensive vaccines, yet it's efficacy rate falls behind the other brands: The issue of Sinovac is not just a matter of price but of efficacy



RELATED: A COVID-19 vaccine developed by China's Sinovac Biotech was just 50.38% effective in late-stage trials in Brazil, significantly lower than earlier results showed, according to a statement published by the government of São Paulo https://t.co/tAReMnP3PR